Mazindol: a risk factor for pulmonary arterial hypertension?

Mazindol is an imidazo-isoindole derivative, tricyclic compound and a non-amphetamine central nervous system stimulant that blocks dopamine and norepinephrine reuptake. Mazindol was withdrawn from the US and European markets in 1999 for reasons unrelated to efficacy or safety around a time when other anorexic drugs were concluded to be associated with the development of pulmonary arterial hypertension (PAH). Despite decades of use, reports of PAH with mazindol have been extremely rare. Recent interest has emerged for mazindol for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD).

http://ift.tt/2mg0gih